Translating G-quadruplex ligands from bench to bedside: a Stephen Neidle’s legacy

IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL
David Monchaud
{"title":"Translating G-quadruplex ligands from bench to bedside: a Stephen Neidle’s legacy","authors":"David Monchaud","doi":"10.1007/s00044-024-03310-3","DOIUrl":null,"url":null,"abstract":"<p>DNA and RNA G-quadruplexes (G4s) are alternative nucleic acid structures that can fold from thousands of guanine (G)-rich sequences in the genome and transcriptome of human cells. Invaluable information about the prevalence and functional relevance of G4s has been gained using G4-specific small molecules (or G4 ligands): cell-based ligand perturbation experiments have indeed provided readouts that were astutely exploited to gain accurate and reliable insights into G4 biology. As a consequence, these investigations have opened the way towards using G4 ligands as drug candidates to fight against genetic diseases, chiefly cancers. This quite active field of research, at the crossroads between chemical biology and medicinal chemistry, thus entirely relies on specific G4 ligands. The greatest contribution to the G4 ligand field is undoubtedly to be attributed to Prof. Stephen Neidle (London, UK). He was indeed the first to design and synthesize G4-interacting compounds, fully characterize their interaction with their G4 targets, and study them in cells with an eye towards benefiting from the central position of G4s in cellular biology to use them as new targets for therapeutic intervention. This review provides an overview of the developments that the G4 ligand field has experienced since the initial impetus provided by Prof. Neidle in 1997, and depicts the trajectories taken by some of them to become ever smarter molecular tools (chemical biology) or drug candidates under clinical assessment (medicinal chemistry).</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"115 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00044-024-03310-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

DNA and RNA G-quadruplexes (G4s) are alternative nucleic acid structures that can fold from thousands of guanine (G)-rich sequences in the genome and transcriptome of human cells. Invaluable information about the prevalence and functional relevance of G4s has been gained using G4-specific small molecules (or G4 ligands): cell-based ligand perturbation experiments have indeed provided readouts that were astutely exploited to gain accurate and reliable insights into G4 biology. As a consequence, these investigations have opened the way towards using G4 ligands as drug candidates to fight against genetic diseases, chiefly cancers. This quite active field of research, at the crossroads between chemical biology and medicinal chemistry, thus entirely relies on specific G4 ligands. The greatest contribution to the G4 ligand field is undoubtedly to be attributed to Prof. Stephen Neidle (London, UK). He was indeed the first to design and synthesize G4-interacting compounds, fully characterize their interaction with their G4 targets, and study them in cells with an eye towards benefiting from the central position of G4s in cellular biology to use them as new targets for therapeutic intervention. This review provides an overview of the developments that the G4 ligand field has experienced since the initial impetus provided by Prof. Neidle in 1997, and depicts the trajectories taken by some of them to become ever smarter molecular tools (chemical biology) or drug candidates under clinical assessment (medicinal chemistry).

Abstract Image

将 G-四链配体从工作台转化到床边:斯蒂芬-奈德尔的遗产
DNA 和 RNA G-四重体(G4s)是一种替代性核酸结构,可由人类细胞基因组和转录组中成千上万个富含鸟嘌呤(G)的序列折叠而成。利用 G4 特异性小分子(或 G4 配体)获得了有关 G4 的普遍性和功能相关性的宝贵信息:基于细胞的配体扰动实验确实提供了读数,利用这些读数可以准确可靠地了解 G4 的生物学特性。因此,这些研究为利用 G4 配体作为候选药物对抗遗传疾病(主要是癌症)开辟了道路。因此,这一处于化学生物学和药物化学交叉点的相当活跃的研究领域完全依赖于特定的 G4 配体。对 G4 配体领域贡献最大的无疑是斯蒂芬-奈德尔教授(英国伦敦)。他是第一个设计和合成与 G4 相互作用的化合物、全面描述这些化合物与 G4 靶点相互作用的人,并在细胞中研究这些化合物,以期利用 G4 在细胞生物学中的核心地位,将它们作为治疗干预的新靶点。本综述概述了 G4 配体领域自 1997 年由 Neidle 教授提供最初动力以来所经历的发展,并描绘了其中一些配体成为更智能的分子工具(化学生物学)或临床评估候选药物(药物化学)的轨迹。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicinal Chemistry Research
Medicinal Chemistry Research 医学-医药化学
CiteScore
4.70
自引率
3.80%
发文量
162
审稿时长
5.0 months
期刊介绍: Medicinal Chemistry Research (MCRE) publishes papers on a wide range of topics, favoring research with significant, new, and up-to-date information. Although the journal has a demanding peer review process, MCRE still boasts rapid publication, due in part, to the length of the submissions. The journal publishes significant research on various topics, many of which emphasize the structure-activity relationships of molecular biology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信